Management of childhood aplastic anemia following liver transplantation for nonviral hepatitis: A French survey

Pediatr Blood Cancer. 2020 Apr;67(4):e28177. doi: 10.1002/pbc.28177. Epub 2020 Jan 11.

Abstract

Background: Hepatitis-associated aplastic anemia (AA) is a rare syndrome combining acute hepatitis of variable severity and AA. Hepatitis may be severe enough to require urgent liver transplantation (LT). Herein, we describe clinical presentation and management of a cohort of pediatric patients diagnosed with AA after undergoing LT for nonviral hepatitis.

Methods: To describe this rare clinical situation, we performed a national survey and identified nine children treated for AA following LT during the last 10 years in France.

Results: All patients were treated first for hepatic failure with urgent LT. AA was diagnosed with a median delay of 34 days [21-200] from the diagnosis of hepatitis. Seven children were treated with antithymocyte globulin/cyclosporine, one with CSA alone and one received bone marrow transplantation. At the last visit (median follow-up: 4 years), outcomes were excellent: all patients were alive and in hematological remission (complete remission: 7; partial remission: 2). Immunosuppressive therapy was pursued in all patients due to the liver transplant. No unusual toxicities were reported.

Conclusion: AA after LT is considered a therapeutic challenge. Nevertheless, hematological outcome is good using a standard immunosuppressive approach.

Keywords: aplastic anemia; children; hepatitis-associated aplastic anemia; liver transplantation.

Publication types

  • Clinical Trial
  • Multicenter Study

MeSH terms

  • Adolescent
  • Anemia, Aplastic* / epidemiology
  • Anemia, Aplastic* / surgery
  • Child
  • Child, Preschool
  • Female
  • Follow-Up Studies
  • France / epidemiology
  • Hepatitis* / epidemiology
  • Hepatitis* / etiology
  • Hepatitis* / therapy
  • Humans
  • Immunosuppression Therapy / adverse effects*
  • Liver Transplantation*
  • Male